Skip to content

Total debt at other companies

LQD
Liquidia CorporationLQDA
$6.96M+1.5%
Revvity logo
RevvityRVTY
$3.94B+17.8%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$3.26B+32,101%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$31.57M-33.1%
Royalty Pharma logo
Royalty PharmaRPRX
Roivant Sciences logo
Roivant SciencesROIV

Other financials

Income statement

See full
Revenue$51.7M+14.1%
Operating income$17.4M+148%
Net income-$13.3M+68.6%
EPS (diluted)-$0.67+69.7%

Balance sheet

See full
Cash & equivalents$115.1M+140%
Total equity$997.3M+25.4%
Total assets$1.5B+69.2%

Cash flow

See full
Operating cash flow$48.7M+291%
CapEx$228.0K+6.5%
Free cash flow$48.5M+289%

Valuation

See full
Market cap$5.51B+96.7%

Profitability

See full
Gross margin91.9%
Operating margin34.5%+23.0pp
Net margin55.9%+35.7pp
FCF margin44.8%+16.8pp

Returns & leverage

See full
Return on equity17.1%+11.5pp
Debt / equity0.0×
Current ratio21.3×+16.0×

Where this comes from

Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $5.08M.

The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ligand Pharmaceuticals's total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ligand Pharmaceuticals's total debt?
Ligand Pharmaceuticals (LGND) reported total debt of $5.08M in Q1 2026.
How has Ligand Pharmaceuticals's total debt changed year-over-year?
Ligand Pharmaceuticals's total debt increased by 14.2% year-over-year, from $4.45M to $5.08M.
What is the long-term trend for Ligand Pharmaceuticals's total debt?
Over 5 years (2020 to 2025), Ligand Pharmaceuticals's total debt has grown at a -23.8% compound annual growth rate (CAGR), from $20.83M to $5.35M.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.